- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05949983
Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer (EMEAPA)
Health Economic Evaluation of an Adapted Physical Activity Program for Women With Breast Cancer During the Active Phase of Treatment: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Scientific rationale: The incidence of breast cancer in women is on the rise again over the period 2010-2018. The overall cost of cancer treatment is 16.8 billion euros, including 3.6 billion for drugs alone. The treatments are more and more prolonged, the proportion of anticancer drugs continues to increase with 10% of the amount reimbursed for drugs delivered in pharmacies in 2017.
Adapted physical activity (APA) was recognized as a non-drug therapy by the HAS in 2011. It reduces certain side effects of treatments, as well as certain symptoms linked to the catabolic activity of the disease such as: fat gain, loss of muscle mass, physical deconditioning, fatigue or pain. For breast cancer, a meta-analysis showed that APA following adjuvant therapy may have a beneficial effect on quality of life. The APA shows in particular for breast cancer, a reduction in all-cause mortality as well as specific mortality and a reduction in recurrence.The prescription of APA has been allowed since the 2016 health law but there is no coverage by the French national health insurance fund (CNAM) despite the benefits shown. APA is only accessible in a few centers in France that have chosen to offer it to patients, thus creating social inequalities in health.
Very few studies have examined the efficiency of APA programs during the active phase of treatment. They related to cohorts of 60 to 165 patients and uses different methods. The investigators decided to set up a study that can measure the efficiency of the standardized APA programs offered to patients diagnosed with breast cancer, assuming that non-drug therapy such as APA would improve the quality of life while reducing health costs.
Description of the procedures: The intervention consists of an initial consultation appointment with a medical check-up and physical tests, then inclusion in the standardized APA program for 6 months. The control group will be offered the same initial consultation appointment with medical check-up and physical tests and will receive recommendations for physical practice as well as a calendar of activities to be practiced independently for 6 months. Inclusion in the APA program will be offered one year after inclusion.
Follow-up: The data will be collected at T0, T + 3 months, T + 6 months, T + 9 months and T + 12 months in both arms. There will be 1 year of data analysis.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie-Eve Rougé-Bugat, MD
- Phone Number: +33 5 61 80 01 23
- Email: marieeve.rouge-bugat@dumg-toulouse.fr
Study Locations
-
-
-
Toulouse, France
- Marie-Eve Rougé-Bugat
-
Contact:
- Marie-Eve Rougé-Bugat, MD
- Phone Number: +33 561800123
- Email: marieeve.rouge-bugat@dumg-toulouse.fr
-
Principal Investigator:
- Marie-Eve Rougé Bugat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- women with breast cancer
- any type of breast cancer, all grades, all stages
- during treatment: surgery +/- chemotherapy +/- radiotherapy +/- hormone therapy
Exclusion Criteria:
- World Health Organization (WHO) 4
- Unstable angina
- Uncontrolled Atrial fibrillation
- Uncontrolled high blood pressure
- Recent myocardial infarction or myocarditis or pericarditis or thromboembolic disease (less than 3 weeks)
- Aortic stenosis or valve disease to operate
- Cardiac or respiratory failure, with dyspnea at rest
- Symptomatic anemia, thrombocytopenia
- Lytic or painful bone metastases, Severe osteoporosis
- Severe infectious syndrome,
- Surgery in the last 3 weeks
- Extreme fatigue, sharp pain, dizziness, disturbance of consciousness, severe undernutrition
- Contraindication to the practice of an adapted physical activity programme
- Currently involved or exclusion period of a interventional study or adapted Physical Activity program
- Patient with protective measures (guardianship, curators, and deprivation of liberty).
- Pregnancy or breastfeeding
- Patient with severe functional limitations
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APA program Group
patients treated and monitored for breast cancer under the APA programme
|
Patients treated and monitored for their breast cancer following the 6-month APA program.
|
Active Comparator: Physical activity recommendation Group
patients treated and monitored for breast cancer who have received recommendations for physical activity
|
Patients treated and monitored for their breast cancer who have received recommendations for physical activity as well as a 6-month activity schedule.
To facilitate patient acceptance and participation in this study, patients who will be randomized to the control group will be offered to follow the APA program after one year of inclusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of physical activity programmes
Time Frame: 12 months
|
Evaluation of the differential cost-utility ratio (cost / QALY), according to the perspective of the community over a 12-month period, of an adapted physical activity program (APA) in comparison to conventional care, including simple recommendations for physical activity for patients with breast cancer during the active phase of treatment.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Breast cancer-specific quality of life
Time Frame: 12 months
|
Breast Cancer Specific Quality of Life Questionnaire (QLQ) (BR23-QLQ-C30) is a 52-item questionnaire.
The choices range from 1 "not at all" to 4 "very much".
|
12 months
|
Clinical efficacy
Time Frame: 12 months
|
Progression-free survival measured for non-metastatic (relapse-free survival) and metastatic (progression-free survival) patients
|
12 months
|
Efficacy on specific functions
Time Frame: 12 months
|
BR23-QLQ-C30 questionnaire. Breast Cancer Specific Quality of Life Questionnaire (BR23-QLQ-C30) is a 52-item questionnaire. The choices range from 1 "not at all" to 4 "very much". |
12 months
|
Society impact (interview)
Time Frame: 12 months
|
Zarit-Burden Interview
|
12 months
|
Society impact
Time Frame: 12 months
|
Number of hours of informal help for basic and instrumental activities of daily life
|
12 months
|
Patient satisfaction
Time Frame: 12 months
|
Patient satisfaction questionnaire (EORTC-IN-PATSAT32) is a 32-item questionnaire.
The choices range from 1 "bad" to 4 "excellent".
|
12 months
|
Programme compliance rate
Time Frame: 12 months
|
Traced by the reservation system for adapted physical activity (APA) sessions
|
12 months
|
Rate of hospital care
Time Frame: 12 months
|
Direct medical costs
|
12 months
|
Rate of difference in the effect of the programme
Time Frame: 12 months
|
Socioeconomic determinants (changes in income, socio-professional category, level of education and family environment)
|
12 months
|
Rate of financial benefit of the programme
Time Frame: 5 years
|
Annual and 5-year net financial benefit of the systematic implementation of an adapted physical activity (APA) program
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marie-Eve Rougé-Bugat, MD, University Toulouse
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/21/0339
- 2022-A00017-36 (Other Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasm
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
-
National Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast CarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterU.S. Army Medical Research and Development Command; U.S. Army Medical Research...CompletedBreast Carcinoma | Malignant Breast Neoplasm | Benign Breast NeoplasmUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | HER2-Positive Breast CarcinomaUnited States
-
Indiana UniversityIndiana University HealthCompletedBreast Cancer | Breast Neoplasms | Anxiety | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Human Mammary Carcinoma | Mammary Neoplasm, Human | Mammary Carcinoma | Neoplasm Remission, Spontaneous | Spontaneous Neoplasm Regression | Regression,... and other conditionsUnited States
-
Umbria Bioengineering TechnologiesToscana Life Sciences Sviluppo s.r.l.; London South Bank University; ELAROS 24... and other collaboratorsRecruitingWomen's Health: Neoplasm of BreastItaly, Spain, Poland, Portugal, Switzerland
-
Istanbul Aydın UniversityActive, not recruiting
-
University of OviedoCompletedWomen's Health: Neoplasm of BreastSpain
-
National Cancer Institute, ThailandCompleted
-
National Cancer Institute, ThailandCompleted
Clinical Trials on APA Program
-
GERCOR - Multidisciplinary Oncology Cooperative...Active, not recruitingMetastatic Pancreatic Cancer | Unresectable Locally Advanced CancerFrance
-
Centre Hospitalier Universitaire de BesanconGERCOR - Multidisciplinary Oncology Cooperative GroupRecruiting
-
Centre Henri BecquerelUnknown
-
University Hospital, RouenNot yet recruiting
-
Centre Hospitalier Universitaire de BesanconNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruitingChronic Fatigue SyndromeFrance
-
Fondation Santé des Étudiants de FranceNot yet recruitingAnorexia NervosaFrance
-
Centre Hospitalier Régional Metz-ThionvilleUniversity of LorraineRecruitingAnxiety | Hematological Malignancies | Relaxation | Adapted Physical ActivityFrance
-
University Hospital, LimogesTerminated